EBOS Group Ltd reported a 9.9% rise in revenue to AUD 13.5 billion for the fiscal year ended June 30, 2026, as underlying EBITDA increased 5.0% to AUD 614 million. The group’s statutory EBITDA rose 7.8% year-on-year, while underlying net profit after tax reached AUD 250 million. Shares rose 5.5% to AUD 23 following the release.
The healthcare division, which accounts for the majority of revenue, grew 8.5% to AUD 12.6 billion, with EBITDA up 3.2% to AUD 516 million. The animal care division, the fastest-growing segment, posted a 34.6% revenue increase to AUD 907 million and EBITDA growth of 11.6% to AUD 138 million. Branded revenue in the division rose 6.7%. Retail pharmacy brands reported network sales of nearly AUD 2.9 billion, supported by 7.6% like-for-like growth across the TerryWhite Chemmart network and an 8.5% rise in dispensary sales.
Capital expenditure for the year totaled AUD 145 million, down from AUD 230 million in the prior period, as the group completed a AUD 360 million distribution center renewal program—the largest infrastructure investment in its history. The new Kemps Creek facility in New South Wales now operates about 20% more productively than the Greystanes site it replaced, with a target 30% productivity uplift by the end of FY2027. Free cash flow for the year reached AUD 204 million, while net working capital increased only AUD 7 million despite 10% revenue growth.
EBOS deployed AUD 121 million across eight bolt-on acquisitions in FY2026, including Paringa Pet Foods, K-Talyst, MediAdvice, and Next Generation Pet Foods. The group retains additional M&A capacity of approximately AUD 150 million through FY2027, assuming leverage remains within its target range of 1.7 to 2.3 times. Group leverage stood at 2.1 times at year-end.
FY2027 guidance calls for underlying EBITDA of AUD 635 million to AUD 655 million, implying about 5% growth at the midpoint. The healthcare distribution and Symbion divisions are expected to grow slightly below the group average, while retail pharmacy brands, medical technology, and animal care are projected to outperform. Capital expenditure is forecast to decline to AUD 100 million, with 55% allocated to maintenance and safety and the remainder to growth projects.
Group CEO Adam Hall said the company met its commitments while completing a major investment phase. Group CFO Alistair Gray noted that lower capex, stronger cash flow, and continued earnings growth position the group to reduce leverage while funding growth investments.
